{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T15:50:42Z","timestamp":1762876242991,"version":"3.40.5"},"reference-count":40,"publisher":"Public Library of Science (PLoS)","issue":"12","license":[{"start":{"date-parts":[[2020,12,22]],"date-time":"2020-12-22T00:00:00Z","timestamp":1608595200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100010661","name":"Horizon 2020 Framework Programme","doi-asserted-by":"crossref","award":["681032"],"award-info":[{"award-number":["681032"]}],"id":[{"id":"10.13039\/100010661","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:p>The ongoing coronavirus disease 2019 (COVID-19) pandemic emerged in December 2019. Convalescent plasma represents a promising COVID-19 treatment. Here, we report on the manufacturing of a plasma-based product containing antibodies specific to SARS-CoV-2 obtained from recently recovered COVID-19 patients. Convalescent plasma donors were screened as follows: 1) previously confirmed SARS-CoV-2 infection (by real-time PCR (RT-PCR)); 2) a subsequent negative PCR test followed by a 2-week waiting period; 3) an additional negative PCR test prior to plasmapheresis; and 4) confirmation of the presence of SARS-CoV-2 specific antibodies. Convalescent plasma was stored fresh (2\u20136\u00b0C) for up to 5 days or frozen (-30\u00b0C) for long-term storage. Donor peripheral blood and final plasma product were assayed for binding antibodies targeting the SARS-CoV-2 S-protein receptor-binding domain (RBD) and their titers measured by an enzyme-linked immunosorbent assay (ELISA). We performed 72 plasmaphereses resulting in 248 final products. Convalescent plasma contained an RBD-specific antibody titer (IgG) ranging from 1:100 to 1:3200 (median 1:800). The titer was congruent to the titer of the blood (n = 34) before collection (1:100\u20131:6400, median 1:800). Levels of IL-8 and LBP of donors were slightly increased. Therapeutic products derived from a human origin must undergo rigorous testing to ensure uniform quality and patient safety. Whilst previous publications recommended RBD-specific binding antibody titers of \u2265 1:320, we selected a minimum titer of 1:800 in order to maximize antibody delivery. Production of highly standardized convalescent plasma was safe, feasible and was readily implemented in the treatment of severely ill COVID-19 patients.<\/jats:p>","DOI":"10.1371\/journal.pone.0243967","type":"journal-article","created":{"date-parts":[[2020,12,22]],"date-time":"2020-12-22T18:31:27Z","timestamp":1608661887000},"page":"e0243967","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":11,"title":["Manufacturing of convalescent plasma of COVID-19 patients: Aspects of quality"],"prefix":"10.1371","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4115-8405","authenticated-orcid":true,"given":"Viola","family":"H\u00e4hnel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Peterhoff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Veronika","family":"B\u00e4uerlein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreas-Michael","family":"Brosig","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Irene","family":"Pamler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9942-672X","authenticated-orcid":true,"given":"Christian","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adelina","family":"Bica","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Monica","family":"Totir","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Ossner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbara","family":"Stemmer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martina","family":"Toelge","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anja","family":"Sch\u00fctz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hans-Helmut","family":"Niller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbara","family":"Schmidt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ralf","family":"Wagner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andr\u00e9","family":"Gessner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ralph","family":"Burkhard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Offner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2020,12,22]]},"reference":[{"issue":"7798","key":"pone.0243967.ref001","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/s41586-020-2012-7","article-title":"A pneumonia outbreak associated with a new coronavirus of probable bat origin","volume":"579","author":"P Zhou","year":"2020","journal-title":"Nature"},{"issue":"10223","key":"pone.0243967.ref002","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/S0140-6736(20)30211-7","article-title":"Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study","volume":"395","author":"N Chen","year":"2020","journal-title":"Lancet"},{"issue":"5","key":"pone.0243967.ref003","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/S2213-2600(20)30079-5","article-title":"Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study","volume":"8","author":"X Yang","year":"2020","journal-title":"Lancet Respir Med"},{"key":"pone.0243967.ref004","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.ijid.2020.03.071","article-title":"Insight into 2019 novel coronavirus\u2014An updated interim review and lessons from SARS-CoV and MERS-CoV","volume":"94","author":"M Xie","year":"2020","journal-title":"Int J Infect Dis"},{"key":"pone.0243967.ref005","article-title":"SARS-CoV-2 (COVID-19) structural and evolutionary dynamicome: Insights into functional evolution and human genomics","author":"R Gupta","year":"2020","journal-title":"J Biol Chem"},{"issue":"3","key":"pone.0243967.ref006","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.dsx.2020.03.012","article-title":"Contentious issues and evolving concepts in the clinical presentation and management of patients with COVID-19 infectionwith reference to use of therapeutic and other drugs used in Co-morbid diseases (Hypertension, diabetes etc)","volume":"14","author":"R Gupta","year":"2020","journal-title":"Diabetes Metab Syndr"},{"issue":"7","key":"pone.0243967.ref007","doi-asserted-by":"crossref","first-page":"102554","DOI":"10.1016\/j.autrev.2020.102554","article-title":"Convalescent plasma in Covid-19: Possible mechanisms of action","volume":"19","author":"M Rojas","year":"2020","journal-title":"Autoimmun Rev"},{"key":"pone.0243967.ref008","article-title":"The possible pathophysiology mechanism of cytokine storm in elderly adults with COVID-19 infection: the contribution of \"inflame-aging\"","author":"GH Meftahi","year":"2020","journal-title":"Inflamm Res"},{"issue":"6","key":"pone.0243967.ref009","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.jinf.2020.03.037","article-title":"The pathogenesis and treatment of the `Cytokine Storm' in COVID-19","volume":"80","author":"Q Ye","year":"2020","journal-title":"J Infect"},{"key":"pone.0243967.ref010","article-title":"Should patients with obesity be more afraid of COVID-19?","author":"AM Rychter","year":"2020","journal-title":"Obes Rev"},{"issue":"7","key":"pone.0243967.ref011","doi-asserted-by":"crossref","first-page":"6049","DOI":"10.18632\/aging.103000","article-title":"Does comorbidity increase the risk of patients with COVID-19: evidence from meta-analysis","volume":"12","author":"B Wang","year":"2020","journal-title":"Aging (Albany NY)"},{"issue":"5","key":"pone.0243967.ref012","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1007\/s11886-020-01292-3","article-title":"Cardiovascular Complications in Patients with COVID-19: Consequences of Viral Toxicities and Host Immune Response","volume":"22","author":"H Zhu","year":"2020","journal-title":"Curr Cardiol Rep"},{"issue":"1","key":"pone.0243967.ref013","doi-asserted-by":"crossref","first-page":"69","DOI":"10.5582\/bst.2020.01020","article-title":"Drug treatment options for the 2019-new coronavirus (2019-nCoV)","volume":"14","author":"H Lu","year":"2020","journal-title":"Biosci Trends"},{"issue":"1","key":"pone.0243967.ref014","doi-asserted-by":"crossref","first-page":"72","DOI":"10.5582\/bst.2020.01047","article-title":"Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies","volume":"14","author":"J Gao","year":"2020","journal-title":"Biosci Trends"},{"issue":"1","key":"pone.0243967.ref015","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.tracli.2015.12.003","article-title":"Plasma therapy against infectious pathogens, as of yesterday, today and tomorrow","volume":"23","author":"O Garraud","year":"2016","journal-title":"Transfus Clin Biol"},{"issue":"1","key":"pone.0243967.ref016","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1007\/s10096-004-1271-9","article-title":"Use of convalescent plasma therapy in SARS patients in Hong Kong","volume":"24","author":"Y Cheng","year":"2005","journal-title":"Eur J Clin Microbiol Infect Dis"},{"issue":"9","key":"pone.0243967.ref017","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.3201\/eid2209.151164","article-title":"Feasibility of Using Convalescent Plasma Immunotherapy for MERS-CoV Infection, Saudi Arabia","volume":"22","author":"YM Arabi","year":"2016","journal-title":"Emerg Infect Dis"},{"key":"pone.0243967.ref018","article-title":"Convalescent Plasma to Treat COVID-19: Possibilities and Challenges","author":"JD Roback","year":"2020","journal-title":"JAMA"},{"issue":"3","key":"pone.0243967.ref019","doi-asserted-by":"crossref","first-page":"102790","DOI":"10.1016\/j.transci.2020.102790","article-title":"Treatment for emerging viruses: Convalescent plasma and COVID-19","volume":"59","author":"BL Brown","year":"2020","journal-title":"Transfus Apher Sci"},{"key":"pone.0243967.ref020","first-page":"CD013600","article-title":"Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a living systematic review","volume":"10","author":"KL Chai","year":"2020","journal-title":"Cochrane Database Syst Rev"},{"key":"pone.0243967.ref021","first-page":"CD013600","article-title":"Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a rapid review","volume":"5","author":"SJ Valk","year":"2020","journal-title":"Cochrane Database Syst Rev"},{"key":"pone.0243967.ref022","article-title":"Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma","author":"C Shen","year":"2020","journal-title":"JAMA"},{"key":"pone.0243967.ref023","article-title":"Effect of Convalescent Plasma Therapy on Viral Shedding and Survival in COVID-19 Patients","author":"QL Zeng","year":"2020","journal-title":"J Infect Dis"},{"issue":"17","key":"pone.0243967.ref024","doi-asserted-by":"crossref","first-page":"9490","DOI":"10.1073\/pnas.2004168117","article-title":"Effectiveness of convalescent plasma therapy in severe COVID-19 patients","volume":"117","author":"K Duan","year":"2020","journal-title":"Proc Natl Acad Sci U S A"},{"key":"pone.0243967.ref025","article-title":"The Rules Governing Medicinal Products in the European Union. Good manufacturing practice (GMP) Guidelines","volume":"4","author":"E Commission","year":"2016","journal-title":"EudraLex"},{"key":"pone.0243967.ref026","article-title":"A highly specific and sensitive serological assay detects SARS-CoV-2 antibody levels in COVID-19 patients that correlate with neutralization","author":"D Peterhoff","year":"2020","journal-title":"Infection"},{"key":"pone.0243967.ref027","doi-asserted-by":"crossref","first-page":"2768","DOI":"10.3389\/fimmu.2018.02768","article-title":"Bactericidal\/Permeability-Increasing Protein Is an Enhancer of Bacterial Lipoprotein Recognition","volume":"9","author":"S Bulow","year":"2018","journal-title":"Front Immunol"},{"issue":"3","key":"pone.0243967.ref028","doi-asserted-by":"crossref","DOI":"10.2807\/1560-7917.ES.2020.25.3.2000045","article-title":"Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR","volume":"25","author":"VM Corman","year":"2020","journal-title":"Euro Surveill"},{"issue":"6","key":"pone.0243967.ref029","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1111\/trf.15801","article-title":"Bacterial contamination rates in extracorporeal photopheresis","volume":"60","author":"I Pamler","year":"2020","journal-title":"Transfusion"},{"issue":"10223","key":"pone.0243967.ref030","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S0140-6736(20)30183-5","article-title":"Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China","volume":"395","author":"C Huang","year":"2020","journal-title":"Lancet"},{"key":"pone.0243967.ref031","unstructured":"Richtlinie zur Gewinnung von Blut und Blutbestandteilen und zur Anwendung von Blutprodukten, (2017)."},{"key":"pone.0243967.ref032","article-title":"Analysis of humoral immune responses in SARS-CoV-2 infected patients","author":"L Henss","year":"2020","journal-title":"J Infect Dis"},{"issue":"suppl 1","key":"pone.0243967.ref033","first-page":"1","article-title":"Investigating the correlation between symptom severity and antibody titer in COVID-19 convalescent plasma donors","volume":"47","author":"SB Ossner T","year":"2020","journal-title":"Tranfus Med Hemother"},{"issue":"supp 1","key":"pone.0243967.ref034","first-page":"1","article-title":"Changes of antibody titer after repeated donations of convalescent plasma by donors recovered from COVID-19","volume":"47","author":"AF Bica","year":"2020","journal-title":"Tranfus Med Hemother"},{"issue":"2","key":"pone.0243967.ref035","first-page":"152","article-title":"Convalescent plasma: new evidence for an old therapeutic tool?","volume":"14","author":"G Marano","year":"2016","journal-title":"Blood Transfus"},{"key":"pone.0243967.ref036","doi-asserted-by":"crossref","first-page":"100069","DOI":"10.1016\/j.jtauto.2020.100069","article-title":"Why will it never be known if convalescent plasma is effective for COVID-19","volume":"3","author":"M Rojas","year":"2020","journal-title":"J Transl Autoimmun"},{"key":"pone.0243967.ref037","unstructured":"An EU programme of COVID-19 convalescent plasma collection and transfusion. 2020."},{"issue":"5","key":"pone.0243967.ref038","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1093\/jac\/dki346","article-title":"Experience of using convalescent plasma for severe acute respiratory syndrome among healthcare workers in a Taiwan hospital","volume":"56","author":"KM Yeh","year":"2005","journal-title":"J Antimicrob Chemother"},{"issue":"4","key":"pone.0243967.ref039","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/j.dsx.2020.05.020","article-title":"Obesity as a predictor for a poor prognosis of COVID-19: A systematic review","volume":"14","author":"A Tamara","year":"2020","journal-title":"Diabetes Metab Syndr"},{"issue":"1","key":"pone.0243967.ref040","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1093\/toxsci\/kfq134","article-title":"Blood cytokines as biomarkers of in vivo toxicity in preclinical safety assessment: considerations for their use","volume":"117","author":"JM Tarrant","year":"2010","journal-title":"Toxicol Sci"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0243967","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,12,22]],"date-time":"2020-12-22T18:31:49Z","timestamp":1608661909000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0243967"}},"subtitle":[],"editor":[{"given":"Luisa","family":"Gregori","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2020,12,22]]},"references-count":40,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2020,12,22]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0243967","relation":{},"ISSN":["1932-6203"],"issn-type":[{"type":"electronic","value":"1932-6203"}],"subject":[],"published":{"date-parts":[[2020,12,22]]}}}